Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5009791 | 0.98 | GAA (0.51) | GAAMEN1KMT2APOLBTSHR | |
| SCHEMBL5013525 | 0.90 | GAA (0.46) | GAAMEN1KMT2APOLBTSHR | |
| SCHEMBL3559531 | 0.80 | POLB (0.50) | GAAMEN1KMT2APOLBTSHR | |
| SCHEMBL17562968 | 0.80 | GAA (0.51) | GAAMEN1KMT2APOLBTSHR | |
| SCHEMBL30475734 | 0.79 | ALDH1A1 (0.41) | GAAMEN1KMT2APOLBTSHR | |
| SCHEMBL223413 | 0.79 | GAA (0.49) | GAAMEN1KMT2ATSHRHSD17B10 | |
| SCHEMBL358889 | 0.79 | ALDH1A1 (0.47) | GAAMEN1KMT2ATSHRHSD17B10 | |
| SCHEMBL263098 | 0.79 | ALDH1A1 (0.47) | GAAMEN1KMT2ATSHRHSD17B10 | |
| SCHEMBL3643406 | 0.77 | ALDH1A1 (0.46) | GAAMEN1KMT2ATSHRHSD17B10 | |
| SCHEMBL193631 | 0.77 | LMNA (0.50) | GAAMEN1KMT2ATSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 181 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2182950-B1 | USE OF 4-(PYRROLIDIN-1-YL)QUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | HELPERBY THERAPEUTICS LTD (GB) | 2017-07-19 | — | — | EP | claimed |
| EP-3092227-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS BROMODOMAIN INHIBITORS | ORION CORPORATION (FI) | 2016-11-16 | — | — | EP | claimed |
| EP-2776445-B1 | THERAPEUTICALLY ACTIVE THIAZOLO-PYRIMIDINE DERIVATIVES | UCB BIOPHARMA SPRL (BE) | 2016-08-10 | — | — | EP | claimed |
| US-9382197-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2016-07-05 | — | — | US | claimed |
| WO-2015104653-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS BROMODOMAIN INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2015-07-16 | — | — | WO | claimed |
| US-7858644-B2 | EP4 receptor antagonists | ASTERAND UK LIMITED (GB) | 2010-12-28 | — | — | US | claimed |
| EP-2217237-A1 | ARYL-SUBSTITUTED BRIDGED OR FUSED DIAMINES AS MODULATORS OF LEUKOTRIENE A4 HYDROLASE | Janssen Pharmaceutica N.V. (BE) | 2010-08-18 | — | — | EP | claimed |
| US-20090143437-A1 | EP4 RECEPTOR ANTAGONISTS | ASTERAND UK LIMITED (GB) | 2009-06-04 | — | — | US | claimed |
| WO-2009058347-A1 | ARYL-SUBSTITUTED BRIDGED OR FUSED DIAMINES AS MODULATORS OF LEUKOTRIENE A4 HYDROLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-05-07 | — | — | WO | claimed |
| US-20090111794-A1 | Aryl-substituted bridged or fused diamines as modulators of leukotriene A4 hydrolase | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-30 | — | — | US | claimed |
| WO-2002018378-A1 | PYRROLIDINE DERIVATIVES AND THEIR USE AS CHYMASE INHIBITOR | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2002-03-07 | — | — | WO | claimed |
| US-6331556-B2 | BENZOFURAN-4-CARBOXYLIC ACID AMIDE DERIVATIVES USED AS PHOSPHODIESTERASE IV OR TUMOR NECROSIS FACTOR INHIBITORS | DARWIN DISCOVERY, LTD. (GB) | 2001-12-18 | — | — | US | claimed |
| US-6313116-B1 | PHOSPHODIESTERASE INHIBITORS | DARWIN DISCOVERY, LTD. (GB) | 2001-11-06 | — | — | US | claimed |
| US-20010031777-A1 | Heterocyclic compounds and their therapeutic use | DARWIN DISCOVERY LIMITED (GB) | 2001-10-18 | — | — | US | claimed |
| WO-2001058896-A1 | BENZOXAZOLE DERIVATIVES AS TNF AND PDE IV INHIBITORS | DARWIN DISCOVERY LIMITED (GB) | 2001-08-16 | — | — | WO | claimed |
| WO-2001058897-A1 | BENZTHIAZOLES AS TNF AND PDE-IV INHIBITORS | DARWIN DISCOVERY LIMITED (GB) | 2001-08-16 | — | — | WO | claimed |
| WO-2001058895-A1 | BENZOFURAN CARBOXAMIDES AND THEIR THERAPEUTIC USE | DARWIN DISCOVERY LIMITED (GB) | 2001-08-16 | — | — | WO | claimed |
| EP-1086106-A1 | FUROPYRIDINE DERIVATIVES AND THEIR THERAPEUTICAL USE | Darwin Discovery Limited (GB) | 2001-03-28 | — | — | EP | claimed |
| US-6169090-B1 | FOR INHIBITION OF PHOSPHODIESTERASE IV | DARWIN DISCOVERY, LTD. (GB) | 2001-01-02 | — | — | US | claimed |
| WO-1999064423-A1 | FUROPYRIDINE DERIVATIVES AND THEIR THERAPEUTICAL USE | DARWIN DISCOVERY LIMITED (GB) | 1999-12-16 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111794-A1 | Aryl-substituted bridged or fused diamines as modulators of leukotriene A4 hydrolase | LTA4H, LTB4R, LTC4S | GAA 1443/4885MEN1 3974/4885KMT2A 2154/4885 |
| US-20090143437-A1 | EP4 RECEPTOR ANTAGONISTS | PTGER4, NR4A1, NR4A2 | GAA 4885/4885MEN1 3375/4885KMT2A 3371/4885 |
| US-20010031777-A1 | Heterocyclic compounds and their therapeutic use | CYP2F1, CYP11B2, CYP3A7 | GAA 2249/4885MEN1 649/4885KMT2A 2401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.